Ad
related to: china coronavirus medicine name
Search results
Results From The WOW.Com Content Network
During the COVID-19 pandemic, the government of the People's Republic of China (PRC) approved the use of Lianhua Qingwen for mild to moderate COVID-19 cases in January 2020, and promotes the use of the medicine abroad. [3] [12] In March 2022, during the Shanghai COVID-19 outbreak, the medication was distributed en masse to residents. Reports ...
The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, [2] the Sinopharm COVID-19 vaccine, [3] or BIBP vaccine, [3] [4] [5] is one of two whole inactivated virus COVID-19 vaccines developed by Sinopharm's Beijing Institute of Biological Products (sometimes written as Beijing Bio-Institute of Biological Products, [6] resulting in the two ...
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, [37] is an mRNA vaccine [156] produced by the German company BioNTech and the American company Pfizer. [ 156 ] [ 157 ] [ 158 ] In Hong Kong, Macau, and Taiwan, Comirnaty is distributed by Fosun Pharma .
On 1 March 2021, Zhong Nanshan said that the vaccination rate of COVID-19 vaccine in China was currently 3.56%, and the Chinese Center for Disease Control and Prevention hoped the rate reach 40% by the end of June 2021. [9] Since late March 2021, the authorities has accelerated the promotion of free COVID-19 vaccination for the whole population ...
Chinese Academy of Medical Sciences COVID-19 vaccine, or IMBCAMS COVID-19 vaccine, traded as Covidful (Chinese: 科维福; pinyin: Kēwéifú), is a COVID-19 vaccine developed by Institute of Medical Biology, Chinese Academy of Medical Sciences .
In contrast to other mRNA COVID-19 vaccines, such as those by Pfizer-BioNTech and Moderna, this vaccine primarily targets the SARS-CoV-2 receptor-binding domain of the spike protein, rather than the entire spike protein. [4] It is approved for Phase III trials in China, [5] Mexico, [6] Indonesia, [7] and Nepal. [8]
In April 2021, CanSino Biologics began clinical trials for a version of its Covid-19 vaccine administered by inhalation rather than injection. [16] Rollout of inhaled boosters began in China in October 2022. [17] Convidecia is approved for use by some countries in Asia, [18] [19] [20] Latin America, [21] [22] [23] and by Hungary.
11 formulations based on the NRICM101 prescription. NRICM101 (Chinese: 清冠一號; Taiwan: Chingguan Yihau; Mainland: Qīng-guān Yī-hào), is a treatment for COVID-19 developed in Taiwan using Traditional Chinese Medicine (TCM), created by the National Research Institute of Chinese Medicine (NRICM), a governmental body of Taiwan. [1]